Fig. 1: Outcomes of de novo versus therapy-related t(8;21) and inv(16) cases.
From: Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
Comparison of the overall survival (a, b), event-free survival (c, d), and cumulative incidence of hematological relapse (e, f) between de novo and therapy-related cases in t(8;21) and inv(16).
